01 July 2005 : Extended abstract from EFAS 2011
Med Sci Monit 2005; 11(7): BR253-257 :: ID: 16978
Background: Background: There is now accumulating evidence that matrixmetalloproteinases and apoptosis may play an important role in inflammation processes. This study wasundertaken to determine the effect of dexamethasone on apoptosis and matrix metalloproteinase 2 (MMP-2)activity compared with two nonsteroidal anti-inflammatory drugs (NSAIDs), piroxicam and diclofenac. Material/Methods:A fibrosarcoma (WEHI-164) cell line was used for evaluating tolerability, MMP-2 activity, and apoptosis.Dexamethasone, piroxicam, and diclofenac were used at concentrations of 10-200 microg/ml in triplicate,two-fold dilutions. MMP-2 activity was assessed using zymography. For assessment of apoptosis, terminaldeoxyribonucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) was used. Results: Cytotoxicityanalysis of dexamethasone showed a greater tolerability than diclofenac at concentrations of 10-100 microg/ml,whereas the cytotoxic effect of dexamethasone and piroxicam were parallel at doses of 5-80 microg/ml.The dose-dependent inhibitory effect of dexamethasone on MMP-2 activity was significantly less than thatof the tested NSAIDs at concentrations of 10-80 microg/ml, while it increased at doses of >100 microg/mlcompared with piroxicam. Moreover, the rate of apoptosis for dexamethasone-treated cells was 20.92%,the values for diclofenac and piroxicam being 78% and 28.15%, respectively. Conclusions: Our findingssuggest that dexamethasone is able to induce apoptosis and suppress MMP-2 activity. Collectively, dexamethasonemight be assumed as an agent which could be recommended for chemopreventive purposes.
Keywords: Dexamethasone - pharmacology, Diclofenac - pharmacology, Matrix Metalloproteinase 2 - antagonists & inhibitors, Piroxicam - pharmacology, Anti-Inflammatory Agents, Non-Steroidal - pharmacology, Antineoplastic Agents - pharmacology, Cell Survival - drug effects, Dexamethasone - pharmacology, Diclofenac - pharmacology, Fibrosarcoma, In Situ Nick-End Labeling, Matrix Metalloproteinase 2 - metabolism, Matrix Metalloproteinase Inhibitors, Piroxicam - pharmacology
01 May 2022 : EditorialEditorial: Cardiovascular Complications at One Year After SARS-CoV-2 Infection are Independent of Underlying Cardiovascular Risk Factors or Severity of COVID-19
Med Sci Monit 2022; 28:e937048
04 May 2022 : Clinical ResearchEffects of Wearing Face Masks on Exercise Capacity and Ventilatory Anaerobic Threshold in Healthy Subjects ...
Med Sci Monit In Press; DOI: 10.12659/MSM.936069
27 May 2022 : Clinical ResearchFactors Associated with Falls During Hospitalization for Coronavirus Disease 2019 (COVID-19)
Med Sci Monit 2022; 28:e936547
27 May 2022 : Clinical ResearchPrognostic Significance of Preoperative Integrated Liver Inflammatory Score in Patients with Hepatocellular...
Med Sci Monit In Press; DOI: 10.12659/MSM.937005
25 May 2022 : Review articleNarrative Review of the Mechanism of Hip Prosthesis Dislocation and Methods to Reduce the Risk of Dislocation
Med Sci Monit In Press; DOI: 10.12659/MSM.935665
24 May 2022 : Clinical ResearchRemimazolam Tosilate Sedation with Adjuvant Sufentanil in Chinese Patients with Liver Cirrhosis Undergoing ...
Med Sci Monit In Press; DOI: 10.12659/MSM.936580
Most Viewed Current Articles
30 Dec 2021 : Clinical ResearchRetrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review articleA Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...
Med Sci Monit 2022; 28:e936292
01 Nov 2020 : Review articleLong-Term Respiratory and Neurological Sequelae of COVID-19
Med Sci Monit 2020; 26:e928996